Cargando…

Editorial: Emerging Therapies for Malignant Mesothelioma

Detalles Bibliográficos
Autores principales:	van Zandwijk, Nico, Reid, Glen, Baas, Paul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7304317/ https://www.ncbi.nlm.nih.gov/pubmed/32596157 http://dx.doi.org/10.3389/fonc.2020.00939

Ejemplares similares

Manipulating microRNAs for the Treatment of Malignant Pleural Mesothelioma: Past, Present and Future
por: Reid, Glen, et al.
Publicado: (2020)

The Immune Microenvironment in Mesothelioma: Mechanisms of Resistance to Immunotherapy
por: Chu, Gerard J., et al.
Publicado: (2019)

Cilengitide Inhibits Attachment and Invasion of Malignant Pleural Mesothelioma Cells through Antagonism of Integrins αvβ3 and αvβ5
por: Cheng, Ngan Ching, et al.
Publicado: (2014)

Immunotherapy in Malignant Pleural Mesothelioma
por: de Gooijer, Cornedine J., et al.
Publicado: (2020)

Anti-Mesothelin CAR T cell therapy for malignant mesothelioma
por: Castelletti, Laura, et al.
Publicado: (2021)

MicroRNA gene expression signatures in long-surviving malignant pleural mesothelioma patients
por: Lin, Ruby C.Y., et al.
Publicado: (2016)

Tumour suppressor microRNAs contribute to drug resistance in malignant pleural mesothelioma by targeting anti-apoptotic pathways
por: Williams, Marissa, et al.
Publicado: (2019)

Zeolites ameliorate asbestos toxicity in a transgenic model of malignant mesothelioma
por: Fan, Xiyong, et al.
Publicado: (2019)

Editorial: Advances in malignant pleural mesothelioma: Diagnosis, treatment, and molecular mechanisms
por: Mastromarino, Maria Giovanna, et al.
Publicado: (2023)

Transcriptional suppression of the miR-15/16 family by c-Myc in malignant pleural mesothelioma
por: Williams, Marissa, et al.
Publicado: (2019)

Emerging Treatments for Malignant Pleural Mesothelioma: Where Are We Heading?
por: Cantini, Luca, et al.
Publicado: (2020)

New Perspectives on Diagnosis and Therapy of Malignant Pleural Mesothelioma
por: Rossini, Marika, et al.
Publicado: (2018)

Editorial: Epigenetic Modifications in Mesothelioma
por: Cheng, Yuen Yee, et al.
Publicado: (2021)

Hitting the Bull’s-Eye: Mesothelin’s Role as a Biomarker and Therapeutic Target for Malignant Pleural Mesothelioma
por: Yeo, Dannel, et al.
Publicado: (2021)

Long Non Coding RNAs (lncRNAs) Are Dysregulated in Malignant Pleural Mesothelioma (MPM)
por: Wright, Casey M., et al.
Publicado: (2013)

Preclinical Models of Malignant Mesothelioma
por: Testa, Joseph R., et al.
Publicado: (2020)

Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future
por: Nicolini, Fabio, et al.
Publicado: (2020)

Comment on ‘Existing prognostic models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma'
por: Kao, S C-H, et al.
Publicado: (2014)

Editorial: Moving beyond the molecular mechanisms of malignant pleural mesothelioma: Cues for novel biomarkers and drug targets
por: Cavallari, Ilaria, et al.
Publicado: (2023)

Novel Insights Into Mesothelioma Therapy: Emerging Avenues and Future Prospects
por: Kuryk, Lukasz, et al.
Publicado: (2022)

A link between the fibroblast growth factor axis and the miR‐16 family reveals potential new treatment combinations in mesothelioma
por: Schelch, Karin, et al.
Publicado: (2017)

Malignant mesothelioma tumours: molecular pathogenesis, diagnosis, and therapies accompanying clinical studies
por: Sahu, Ram Kumar, et al.
Publicado: (2023)

The Biology of Malignant Mesothelioma and the Relevance of Preclinical Models
por: Blanquart, Christophe, et al.
Publicado: (2020)

Immune Microenvironment and Genetics in Malignant Pleural Mesothelioma
por: Wadowski, Benjamin, et al.
Publicado: (2021)

Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis
por: Kirschner, Michaela B, et al.
Publicado: (2015)

Clinical experience of volumetric modulated arc therapy for malignant pleural mesothelioma after extrapleural pneumonectomy
por: Kimura, Tomoki, et al.
Publicado: (2015)

Oncolytic Viral Therapy for Mesothelioma
por: Pease, Daniel F., et al.
Publicado: (2017)

Development and Validation of a Prognostic Signature for Malignant Pleural Mesothelioma
por: Zhou, Jian-Guo, et al.
Publicado: (2019)

Case report: Rare intrapulmonary malignant mesothelioma complicated with myositis
por: Gong, Dandan, et al.
Publicado: (2022)

Epigenetic Regulation of miRNA Expression in Malignant Mesothelioma: miRNAs as Biomarkers of Early Diagnosis and Therapy
por: Tomasetti, Marco, et al.
Publicado: (2019)

The Use of Immunohistochemistry, Fluorescence in situ Hybridization, and Emerging Epigenetic Markers in the Diagnosis of Malignant Pleural Mesothelioma (MPM): A Review
por: Rozitis, Eric, et al.
Publicado: (2020)

A proteomics-based approach identifies secreted protein acidic and rich in cysteine as a prognostic biomarker in malignant pleural mesothelioma
por: Kao, Steven C, et al.
Publicado: (2016)

Editorial: Advances of Targeted Therapy in Gynecologic Malignancies
por: Qiu, Haifeng, et al.
Publicado: (2022)

Editorial: The Emerging Role for PP2A in Hematologic Malignancies
por: Ruvolo, Peter P.
Publicado: (2016)

Mesothelioma Driver Genes, Ferroptosis, and Therapy
por: Felley-Bosco, Emanuela, et al.
Publicado: (2019)

Cellular Immunotherapy and Locoregional Administration of CAR T-Cells in Malignant Pleural Mesothelioma
por: Belderbos, Robert A., et al.
Publicado: (2020)

Liquid Biopsy in Malignant Pleural Mesothelioma: State of the Art, Pitfalls, and Perspectives
por: Cavallari, Ilaria, et al.
Publicado: (2019)

Aurora Kinase A as a Diagnostic and Prognostic Marker of Malignant Mesothelioma
por: Guo, Zhenying, et al.
Publicado: (2021)

Malignant Pleural Mesothelioma Epidemiology in the United States From 2000 to 2016
por: Thomas, Akesh, et al.
Publicado: (2021)

Lurbinectedin in Refractory Diffuse Malignant Peritoneal Mesothelioma: Report of Two Cases
por: Gros, Louis, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rvvqktjec300jnd0goonc4lall